Caplacizumab (Cablivi) injection is indicated in combination with plasma exchange and immunosuppressive therapy for adults with acquired thrombotic thrombocytopenic purpura (aTTP).
FDA Approvals …read more
Caplacizumab (Cablivi) injection is indicated in combination with plasma exchange and immunosuppressive therapy for adults with acquired thrombotic thrombocytopenic purpura (aTTP).
FDA Approvals …read more